A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease

BACKGROUND: Infliximab is effective in inducing and maintaining remission in patients with Crohn’s disease (CD), but primary non-response (PNR) occurs in 10-30% of cases. We investigated whether serum biomarkers are effective in predicting PNR in patients with CD. METHODS: From January 2016 to April...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Chen, Rirong, Zhang, Yingfan, Zhou, Gaoshi, Chen, Baili, Zeng, Zhirong, Chen, Minhu, Zhang, Shenghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339550/
https://www.ncbi.nlm.nih.gov/pubmed/34367126
http://dx.doi.org/10.3389/fimmu.2021.646673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339550/
https://www.ncbi.nlm.nih.gov/pubmed/34367126
http://dx.doi.org/10.3389/fimmu.2021.646673

Ejemplares similares